



BTC HEALTH SHARE PURCHASE PLAN COMPLETION

BTC health (ASX: BTC) is pleased to report that the Company's Share Purchase Plan (SPP) was well supported, having closed on 7 June 2019 raising \$1,189,700.

The SPP was offered to shareholders at 8 cents per share, which was the same price as the oversubscribed private placement that was completed immediately prior to the announcement of the SPP. 14,871,250 shares will be issued via the SPP. The shares for the SPP will be allotted on 13 June 2019.

The proceeds from the SPP will be used for growth funding of the Hospital Infusion Business that was acquired from Admedus Limited (AHZ.asx) in May 2019. The Hospital Infusion Business is a strategic acquisition giving BTC health a strong platform for growth, an experienced sales team and an established customer base. This infrastructure will be leveraged to deliver organic growth and provide the capability for the introduction of new products from the BTC health pipeline.

Richard Treagus, Executive Chairman commented, "We are very pleased with the positive response and the level of support we have received from our shareholders with this SPP. The hospital infusion business has now been fully integrated into BTC health and products are currently being sold and distributed to hospitals across Australia and New Zealand."

For more information please contact:

Dr. Richard Treagus, Executive Chairman
rtreagus@btchealth.com
+61 417 520 509

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of BTC health to be materially different from the statements in this announcement.

About BTC health

BTC health is a listed entity on the ASX and is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992. The company's strategy is to make active investments in businesses that acquire, develop and commercialize product opportunities in the healthcare space and which will benefit from greater access to development capital. The company has the long-term objective of building a group of complementary high-growth businesses which operate together and generate better patient health outcomes and value for its shareholders.

Under the Pooled Development Funds Act 1992, shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding. Gains realised on the disposal of shares will not be included in an investor's assessable income in Australia. An investor will not be entitled to any deduction or capital loss on the sale of shares. Unfranked dividends received by an Australian resident will be exempt from tax. Franked dividends will also be exempt from tax unless the shareholder elects to be taxed. An Australian corporate tax entity may credit its franking account (with franking credits attaching to a franked dividend), regardless of whether it has elected to treat the dividend

as exempt or assessable income. Dividends paid to non-residents will not be subject to withholding tax. A shareholder or prospective shareholder should obtain their own tax advice rather than relying on this summary